ArticleBreast (Edinburgh, Scotland)2022

Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.

John Hang Leung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.